New funding will support clinical development of two novel therapies to address complications of cystic fibrosis
Site Search
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
Potential treatment from Calithera Biosciences minimizes growth of germs in the lungs
Nonprofit commits $20 million to fund projects and accelerate genetic therapies for CF
A group of nonpartisan patient and consumer organizations issued a statement after passage of the Tax Cuts and Jobs Act.
Palliative care guidelines provide recommendations to help reduce physical and emotional symptoms and improve quality of life for people with cystic fibrosis throughout their lives.
Rushed CBO Score Fails to Show Graham-Cassidy's Devastating Impact on Patients
This competition is awarding one year of free lab and office space at Bakar Labs of University of California Berkeley to applicants with emerging technology in gene editing, gene delivery, and gene therapy/gene insertion that may be applied to CF.
Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2
New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease